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Abstract: A novel method was developed here to prepare albumin-based nanoparticles (NPs) for 
improving the therapeutic and safety profiles of chemotherapeutic agents. This approach involved 
crosslinking bovine serum albumin (BSA) using a Schiff base-containing vanillin, into NPs and 
loading doxorubicin (DOX) into the NPs by incubation. The resultant NPs (DOX-BSA-V-NPs) 
displayed a particle size of 100.5±1.3 nm with a zeta potential of -23.05±1.45 mV and also 
showed high drug-loading efficiency and excellent stability with respect to storage and tem-
perature. The encapsulation of DOX into the BSA-V-NPs was confirmed by dynamic scanning 
calorimetry and Raman spectroscopy. DOX-BSA-V-NPs exhibited a significantly faster DOX 
release at pH 6.5 than pH 7.4, as well as in a solution with a higher glutathione concentration. 
In vitro studies showed that the cellular uptake of DOX-BSA-V-NPs was time-dependent, 
concentration-dependent, and faster than free DOX, while the cytotoxicity of DOX-BSA-V-
NPs (IC
50
 value of 3.693 μg/mL) was superior to free DOX (IC
50
 value of 4.007 μg/mL). More 
importantly, DOX-BSA-V-NPs showed a longer mean survival time of 24.83 days, a higher 
tumor inhibition rate of 56.66%, and a decreased distribution in the heart than other DOX for-
mulations in animal studies using a tumor xenograft model. Thus, the vanillin-based albumin 
NPs were shown here to be a promising carrier for tumor-targeted delivery of chemotherapeutic 
agents and, thus, should be further studied.
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Introduction
Doxorubicin (DOX), the most commonly used anthracycline, has an antineoplastic 
effect on breast, lung, stomach, lymph, and ovary carcinomas.1 However, severe 
toxicities (such as myelosuppression, mucositis, and cardiomyopathy) have limited 
its application in medicine.2,3 The side effects associated with anticancer drugs can be 
remarkably reduced by encapsulating them in nanocarriers.4,5 DOX has been encapsu-
lated in liposomes or pegylated (stealth) liposomes, leading to numerous products on the 
market (Myocet® [Cephalon, Inc., Frazer, PA, USA] and Doxil® [Janssen Biotech, Inc., 
Horsham, PA, USA]/Caelyx® [Ben Venue Laboratories, Inc., Bedford, OH, USA]), 
and liposomal DOX shows a lower drug-related toxicity and similar anticancer activity 
compared to free DOX.6–10 However, the pegylation of liposomes has resulted in a side 
effect called hand-foot syndrome11 (also known as palmar plantar erythrodysesthesia) 
due to the leakage of DOX from capillaries in the palms of the hands and soles of the 
feet. Hence, improving the therapeutic index of DOX has been long pursued.10
Albumin NPs are a most promising carrier for drug delivery due to their bio-
compatibility, biodegradability, and tumor targeting ability because of albumin’s 
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high affinity with the glycoprotein receptor gp60 and 
secreted proteins that are acidic and rich in cysteine. The 
Schiff base has recently attracted considerable attention 
due to its therapeutic potential,12 including antibacterial,13,14 
anticancer,15,16 and antiproliferative activities.17 Bovine 
serum albumin (BSA), a low-cost and readily available 
globular protein, exhibits 76% homology with human serum 
albumin (HSA),18 which is always used to substitute HSA. 
Vanillin, a water-soluble aromatic compound, has been 
widely used as a food supplement and is generally regarded 
to be safe. In our previous work, we developed a thermally 
driven self-assembly method to prepare BSA-vanillin NPs 
(BSA-V-NPs),19 and this method was based on the Schiff 
base which was formed by the chemical reaction between 
the amino groups of BSA and the aldehyde groups of vanil-
lin in an aqueous environment. Moreover, hydrogen bonds 
can be formed between the hydroxyl groups of vanillin 
and albumin. With vanillin as a nontoxic crosslinker, the 
resultant BSA-V-NPs are more stable due to the existence 
of a Schiff base and hydrogen bonds. Besides, a cytotox-
icity study indicated that the BSA-V-NPs have potential 
anticancer activity.
The primary goal of the present study was to improve the 
therapeutic index of DOX by encapsulating it in the BSA-V-
NPs. Tumor delivery and anticancer activities were evaluated 
using human gastric cancer BGC-823 cells and in xenograft 
tumor-bearing mice. Control formulations included free DOX 
and DOX-loaded vanillin-free BSA-NPs (DOX-BSA-NPs). 
Tumor delivery was investigated using cellular uptake and 
in vivo distribution studies, while the anticancer activity was 
further verified by cytotoxicity assays, a survivability study, 
tumor suppression, and histological examination in tumor 
resections after treatment.
Materials and methods
BSA, L-glutathione (GSH), rhodamin B isothiocyanate 
(RBITC), and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindo 
tricarbocyanine iodide (DiR) were purchased from 
Sigma-Aldrich Co. (St Louis, MO, USA). Vanillin was 
obtained from Aladdin Industrial Corporation (Shanghai, 
People’s Republic of China). Doxorubicin hydrochloride 
was supplied by Dalian Meilun Biotech Co. Ltd (Dalian, 
People’s Republic of China). Nystatin was purchased from 
HeFei BoMei Biotechnology Co. Ltd (Hefei, People’s 
Republic of China). Lysotracker Green DND-26, RPMI-
1640 medium, fetal bovine serum, and antibiotics (penicillin 
10,000 units/mL, streptomycin 10,000 μg/mL) were obtained 
from Thermo Fisher Scientific (Waltham, MA, USA). 4′, 
6-Diamidino-2-phenylindole (DAPI) was purchased from 
Vector Laboratories, Inc. (Burlingame, CA, USA). Methanol 
and acetonitrile were of high performance liquid chromatog-
raphy (HPLC) grade, other chemicals and reagents were of 
analytical grade and used as received.
Preparation of DOX-Bsa-V-NPs
BSA-V-NPs were prepared as reported previously.19 Briefly, 
250 mg of BSA and 14.4 mg of vanillin were dissolved in 
50 mL of deionized water and heated at 70°C for 2 hours. 
Generally, 5 mg/mL of a DOX⋅HCl aqueous solution was 
added into the BSA-V-NPs at a proper weight ratio of DOX 
to BSA. The mixture was stored in the dark for 24 hours 
after adjusting the pH with sodium hydroxide (NaOH). The 
obtained NP solution was stored at 4°C before use. The 
DiR-labeled BSA-V-NPs (DiR-BSA-V-NPs) were prepared 
with the same procedure and purified by dialyzing against 
phosphate-buffered saline (PBS) buffer.20 The vanillin-free 
DOX-BSA-NPs were also prepared by incubating DOX with 
BSA-NPs in the dark for 24 hours.
RBITC-labeled BSA-V-NPs (RBITC-BSA-V-NPs) were 
fabricated as previously reported.19 Briefly, RBITC-labeled 
BSA (RBITC-BSA) was synthesized by dissolving BSA in 
carbonate buffer and incubating with RBITC for 2 hours. 
After dialyzing against deionized water for 24 hours, the 
RBITC-BSA was obtained by lyophilization.21 After dissolv-
ing RBITC-BSA and vanillin in deionized water, RBITC-
BSA-V-NPs were obtained by heating the mixture at 70°C 
for 2 hours.
Determination of particle size and zeta 
potential
The particle size of the NPs was determined by dynamic 
light scattering (DLS) (Brookhaven Instrument Corporation, 
Holtsville, NY, USA) with a fixed scattering angle of 90°, 
while the zeta potential of the NPs was measured by the 
Zetaplus zeta potential analyzer (Brookhaven Instrument 
Corporation) at 25°C.
Determination of drug loading efficiency 
and drug encapsulation efficiency
The free DOX was separated by a centrifugal-ultrafiltration 
method, and the DOX content was calculated by the absor-
bance at 480 nm using a calibration curve.22 The amount of 
free BSA in the supernatant of the BSA colloidal solution 
after centrifugation (39,120× g ) at 4°C for 60 minutes was 
determined using the Coomassie® protein assay reagent 
kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, 
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People’s Republic of China).23 Drug loading efficiency (DLE) 
and drug encapsulation efficiency (DEE) of the NPs were 
calculated by the following equations:24
 
DLE (%)
m
m m
encapsulated DOX
encapsulated DOX self-assembly B
=
+
SA
×100%
 
(1)
 
DEE (%)
m
m
encapsulated DOX
DOX in feed
= ×100%
 
(2)
Morphology observation
The colloidal solutions of BSA-V-NPs and DOX-BSA-
V-NPs were separately diluted with deionized water to a 
proper concentration and one droplet was placed on the 
copper grid. After staining with 2% phosphotungstic acid 
for 30 seconds, a transmission electron microscope (TEM, 
H-7650; Hitachi Ltd., Tokyo, Japan) was used to capture 
images of the BSA-NPs.
circular dichroism spectroscopy, dynamic 
scanning calorimetry, and raman 
spectroscopy
To investigate the protein’s structural changes, circular 
dichroism (CD) spectra were obtained on a Jasco J-810 
Spectrometer (Jasco, Tokyo, Japan) at room temperature 
over a wavelength range of 190–260 nm with a scan rate 
of 50 nm/min, response time of 1 second, and BSA con-
centration of 0.1 mg/mL. PBS buffer (pH 7.4) was used as 
the solvent.
Thermal analysis of the DOX, BSA-V-NPs, DOX-BSA-
V-NPs, and mixture of DOX and BSA-V-NPs were performed 
on a differential scanning calorimeter (DSC Q2000; TA 
Instruments, Wilmington, DE, USA) with an integrated 
autosampler. Accurately weighed samples were placed into 
aluminum containers and measured using a programmed scan 
speed of 10°C/min from room temperature to 250°C under 
a nitrogen atmosphere.
The colloidal solutions of BSA-V-NPs and DOX-BSA-
V-NPs were lyophilized for 24 hours after removing the free 
BSA and DOX. The Raman spectra of DOX, BSA-V-NPs, 
DOX-BSA-V-NPs, and the mixture of DOX and BSA-V-NPs 
were recorded by a DXR Raman microscope (Thermo Fisher 
Scientific) equipped with a 780 nm externally stabilized diode 
laser. The digital camera was cooled at -40°C. Spectra were 
acquired over the wavelength range of 3,350–50 cm-1 with 
an exposure time of 2 seconds, 30 times, and using a 50× 
objective and laser power of 24 mW.
stability of DOX-Bsa-V-NPs
The stability of DOX-BSA-V-NPs was investigated by deter-
mining the particle size as a function of time.25 The samples 
were dissolved in 0.9% NaCl and 5% glucose with a protein 
concentration of 1 mg/mL and stored at 37°C for 48 hours.26 
At various time points, the hydrodynamic diameters were 
measured by DLS (Brookhaven Instrument Corporation). 
Meanwhile, the DOX-BSA-V-NPs were also stored at 4°C 
for 2 months and at 40°C for 10 days.
Doxorubicin release in vitro
To obtain in vitro drug release profiles, PBS (pH 7.4 and 
pH 6.5), 10 μM GSH (pH 7.4), and 20 mM GSH (pH 6.5) 
solutions were used as the release media. The solution of 
DOX-BSA-V-NPs (1.8 mL) was dialyzed (MWCO 14 kDa; 
Jinsui Biotechnology Co., Ltd., Shanghai, People’s Republic 
of China) against 23.2 mL of the release buffer at 37°C with 
constant shaking. Three milliliters of the release buffer were 
withdrawn at specific intervals and the same volume of fresh 
medium was added. Each experiment was repeated twice and 
the average data were reported.
cellular uptake and uptake mechanism
Human gastric cancer BGC-823 cells (Ethical approval to use 
this human cancer cell line was not required by China Phar-
maceutical University.) were seeded in 24-well microplates 
at 5.0×104 cells/well and were incubated at 37°C in a 5% CO
2
 
incubator for 24 hours. Then, the cells were incubated with 
the same concentration of free DOX and DOX-BSA-V-NPs. 
After incubation for 0.5, 1, 2, 4, and 8 hours, the medium 
was removed and the cells were washed thrice with cold PBS 
buffer and were fixed with paraformaldehyde for 20 minutes. 
Finally, the uptake of free DOX and DOX-BSA-V-NPs was 
observed by an inverted fluorescence microscope (Olympus 
Corporation, Tokyo, Japan). To investigate the influence of 
DOX concentration on cellular uptake, drug concentrations 
over the range of 0.39–12.48 μg/mL were administered to 
the cells. To semiquantitatively determine the uptake amount, 
BGC-823 cells were seeded and treated as described earlier. 
Then, cells were trypsinized, supplemented with 0.5 mL 
of cell culture medium, and harvested by centrifugation at 
180× g for 5 minutes. The cell pellet was rinsed three times 
with cold PBS buffer, resuspended in 0.5 mL of PBS, and 
analyzed using flow cytometry (BD, Franklin Lakes, NJ, 
USA). To trace cellular uptake behavior, BGC-823 cells 
were also seeded on laser confocal dishes and incubated for 
24 hours, then DOX and DOX-BSA-V-NPs were added sepa-
rately. After washing thrice with cold PBS buffer and staining 
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for 20 minutes with DAPI, the samples were observed with 
a confocal laser scanning microscope (CLSM, TCS-SP5; 
Leica Microsystems, Wetzlar, Germany).
Endocytosis uptake of BSA-V-NPs was investigated by 
endo-lysosomal labeling and pharmacological endocytic 
inhibitors. For this, BGC-823 cells were seeded on the laser 
confocal dishes and incubated for 24 hours. Subsequently, 
a RBITC-BSA-V-NPs solution was added and incubated 
for 4 hours. After removing the NP solution, the cells were 
washed with cold PBS buffer and incubated with LysoTracker 
Green for another 2 hours. After washing thrice and staining 
for 20 minutes with DAPI, the samples were observed with 
a CLSM (TCS-SP5). To further reveal the uptake pathways 
of BSA-V-NPs, BGC-823 cells were preincubated with the 
endocytic inhibitors sucrose (450 mM, inhibiting clathrin-
mediated endocytosis) and nystatin (25 μg/mL inhibiting 
caveolae-mediated endocytosis), respectively.21,27 After 
removing the inhibitor solution, the cells were washed thrice 
and further treated with DOX-BSA-V-NPs for 4 hours. 
Finally, the cells were washed, fixed, and observed using 
an inverted fluorescence microscope (Olympus). The cells 
without inhibitor treatment were used as a control.
cytotoxicity assay
The cytotoxicity of DOX-BSA-V-NPs was determined using 
a cell counting kit-8 (CCK-8) assay (Dojido, Kumamoto, 
Japan) according to the manufacturer’s instructions. BGC-823 
cells were seeded on 96-well microplates at 1.0×104 cells/well 
and incubated in a 5% CO
2
 incubator at 37°C for 24 hours to 
attach to the bottom. After removing the culture media from 
the wells, the DOX-BSA-V-NPs solution was diluted using 
1640 cell culture medium at a series of concentrations added 
into the wells. After incubating at 37°C for 48 hours, the drug 
solution was removed and the CCK-8 solution was added. 
Then, the microplates were incubated for another 1 hour and 
the optical density (OD) of each well was determined by an 
Infinite M200 Pro microplate reader (Tecan, Mannedorf, 
Switzerland). A free Dox solution at the same concentration 
was used as a control. The cell viability (CV) was calculated 
by the equation: CV (%) = OD
sample
/OD
blank
 ×100%, while the 
inhibitory concentration 50% (IC
50
) value was calculated by 
SPSS® Statistics for Windows version 18.0 software (IBM 
Corporation, Armonk, NY, USA).
animals and tumor xenograft models
Institute of Cancer Research mice (male, 25–30 g) were 
obtained from Qinglongshan Animal Breeding Field (Jiangsu, 
People’s Republic of China). The experiments were con-
ducted in full compliance with the Guide for Care and Use 
of Laboratory Animals and approved by the China Pharma-
ceutical University. The tumor-bearing mice were inoculated 
in the subcutaneous dorsa with 100 μL of hepatocellular 
carcinoma (Heps) cells (2×106 cells/mouse).28 Tumor volume 
was calculated using the equation: V = a × b2/2, where a and 
b are the length and width of the tumor, respectively.25
Biodistribution examination in vivo
Heps tumor xenograft mice were used for the in vivo biodis-
tribution study. A noninvasive fluorescent imaging technique 
was used to explore the tumor-targeting ability of BSA-V-
NPs. A DiR-BSA-V-NPs solution in 0.1 mL was injected to 
the Heps tumor-bearing mouse with a DiR dose of 5 mg/kg 
via the tail vein. After 0.5, 1, 4, 6, 12, and 24 hours, the 
anesthetized mouse was introduced into the chamber and 
near-infrared fluorescence (NIRF) images were captured 
by a DXS 4000PRO System (Kodak, Rochester, NY, USA) 
under the same condition.28
The mice were randomly assigned to three treatment groups 
with 24 males in each group and intravenously administered 
separately with free DOX, DOX-BSA-NPs, and DOX-BSA-
V-NPs with a DOX dose of 5 mg/kg after 7 days of the inocu-
lation. The mice were sacrificed at 0.5, 1, 2, 4, 6, 12, 24, and 
48 hours after injection (n=3 at each time point). Subsequently, 
the tumor and heart tissue were collected and measured. After 
homogenization of the tissues with saline, DOX was extracted 
by mixing acetonitrile:methanol:concentrated HCl (66:33:2, 
v:v:v) with the homogenate. Following 2 minutes of vortex 
and centrifugation at 12,000× g for 10 minutes, quantitative 
analysis of the DOX concentration in the supernatant was 
performed by HPLC.28 The data were calculated according to 
the calibration curve and normalized to the tissue weight.
In vivo antitumor efficacy
For the in vivo survival study, the mice were randomly divided 
into four treatment groups with six males in each group. The 
inoculation day was recorded as day 0, and the treatments 
were started 5 days later. Normal saline, free DOX, DOX-
BSA-NPs, and DOX-BSA-V-NPs solutions were injected 
with a DOX dose of 5 mg⋅kg-1⋅day-1 for 3 days, respectively. 
The survival time of each mouse was recorded. Mean survival 
time (MST) of each group and the increase in lifespan (ILS) 
were calculated by the following equations:15
 
MST
Survival time of each mice in a group
Total number of
= ∑
mice  
(3)
 
ILS
MST MST
MST
treated control
control
=








×
−
100
 
(4)
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For the in vivo tumor inhibition test, the Heps tumor-
bearing mice were also intravenously administered with 
normal saline, free DOX, DOX-BSA-NPs, and DOX-BSA-
V-NPs after 3 days of the inoculation with a DOX dose of 
5 mg⋅kg-1⋅day-1 for 3 days. After 10 days of inoculation, 
the animals were sacrificed by cervical dislocation.22,24 
Subsequently, dissection was done, and the tumors and 
hearts were removed for the following studies. The solid 
tumors were harvested and measured, while the hearts 
and tumors were sectioned for histological evaluation by 
hematoxylin and eosin (HE) staining. The tumor inhibition 
rate (TIR) was calculated by the equation:29
 
TIR (%)
V
V
treated
control
= −




×1 100%
 
(5)
where V
–
treated
 is the average tumor volume of the treated 
group, and V
–
control
 is the average tumor volume of the normal 
saline group.
statistical analysis
Data are presented as mean ± SD and were analyzed by 
Student’s t-tests to determine the significance of differences 
between the groups. Statistical significance was set at P,0.05 
and P,0.01.
Results and discussion
Preparation of DOX-Bsa-V-NPs
BSA-V-NPs were fabricated by a thermal driven self-assembly 
method, in which the pH, BSA/vanillin ratio, BSA concen-
tration, and heating temperature were all important factors. 
The optimized preparation conditions were as follows: 
deionized water (pH 6) as a reaction solution; BSA/vanillin 
(mol/mol) at a 1:25 ratio; BSA concentration at 5 mg/mL, 
and heating temperature at 70°C. The particle size, polydis-
persity index (PDI), and zeta potential of the BSA-V-NPs 
were 106.4±1.8 nm, 0.167±0.024, and -20.49±0.72 mV, 
respectively.
The DOX-BSA-V-NPs were prepared by incubating 
DOX⋅HCl with the BSA-V-NPs. To simplify the descrip-
tion, the concentration of BSA-V-NPs was denoted by BSA 
concentration. The initial pH of the mixture of DOX⋅HCl 
and BSA-V-NPs (1:10, w/w) without adjustment was 
around 5, where the charge of NPs was almost neutral. 
Hence, the particles aggregated and the particle size reached 
2,106.3±116.4 nm (Table 1). As the pH value increased, both 
the negative charges in the system and the concentration 
of unprotonated DOX molecules increased. Therefore, the 
interaction between DOX and BSA-V-NPs was enhanced and 
as a result, the BSA-V-NPs possessed a higher DLE and a 
more compact structure (Table 1).24 However, as the amount 
of DOX⋅HCl was fixed, when all the DOX molecules in 
the system were unprotonated, the DLE and DEE would 
be relatively constant. Herein, a pH of 7.4 was chosen in 
the following study due to the satisfactory encapsulation 
efficiency and drug loading.
The influence of BSA/DOX⋅HCl ratio (w/w) on the 
formation of DOX-BSA-V-NPs was also studied. As 
the BSA/DOX⋅HCl ratio decreased, the particle size 
and DLE increased, while the DEE decreased (Table 2). 
Compared with the DOX-BSA-Dextran-NPs reported by 
Deng et al,24 the DOX-BSA-V-NPs possessed a similar 
DLE and DEE at the same BSA/DOX⋅HCl ratio, but a 
slightly larger size. For the sake of investigating the in 
vivo behavior, a BSA/DOX⋅HCl ratio of 10:1, a com-
parable size as the DOX-BSA-NPs (vanillin free), was 
selected. The zeta potential of the resultant NPs was 
–23.05±1.45 mV.
characterization of DOX-Bsa-V-NPs
The morphology of the NPs was observed by the TEM. As 
shown in Figure 1, both the DOX-free NPs and DOX-BSA-V-NPs 
were spherical or ellipsoidal with a diameter ~80–90 nm. 
Table 1 Dls, Dle, and Dee results of DOX-Bsa-V-NPs prepared 
at different ph values with a Bsa/DOX⋅hcl ratio (w/w) of 10:1
pH Particle size nm PDI DLE (%) DEE (%)
Initial ph 2,106.3±116.4 0.349±0.018 – –
6.8 100.5±3.5 0.139±0.037 8.23±1.49 83.49±5.04
7.4 92.7±1.8 0.163±0.013 9.09±0.41 88.60±3.42
7.8 95.4±0.8 0.144±0.052 8.98±0.39 92.09±0.190
Notes: Mean ± standard deviation, n=3; –, not measured.
Abbreviations: BSA, bovine serum albumin; DEE, drug encapsulation efficiency; 
DLE, drug loading efficiency; DLS, dynamic light scattering; DOX, doxorubicin; 
DOX⋅hcl, doxorubicin hydrochloride; NPs, nanoparticles; PDI, polydispersity index; 
V, vanillin; w, weight.
Table 2 Dls, Dle, and Dee results of DOX-Bsa-V-NPs prepared 
at different Bsa/DOX⋅hcl ratios (w/w)
BSA/DOX⋅HCl 
(w/w)
Particle size 
(nm)
PDI DLE (%) DEE (%)
20:1 100.1±0.7 0.139±0.042 4.28±0.23 89.07±5.07
10:1 100.5±1.3 0.122±0.022 8.29±0.049 85.45±6.38
5:1 134.6±4.2 0.150±0.048 13.98±0.24 77.94±1.58
2:1 189.6±5.7 0.245±0.029 27.77±0.50 73.89±1.86
Note: Mean ± standard deviation, n=3.
Abbreviations: BSA, bovine serum albumin; DEE, drug encapsulation efficiency; 
DLE, drug loading efficiency; DLS, dynamic light scattering; DOX, doxorubicin; 
DOX⋅hcl, doxorubicin hydrochloride; NPs, nanoparticles; PDI, polydispersity 
index; V, vanillin; w, weight.
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Compared with the DLS data, the particle size of TEM was 
smaller, since the TEM captured the images of the dried NPs, 
whereas the DLS determined the hydrodynamic diameter.24
The conformational changes of BSA were observed by 
the CD spectra. As shown in Figure 2, the spectra of both 
DOX-loaded and DOX-free BSA-V-NPs exhibited two 
negative peaks ~210 and 220 nm, which were the character-
istic bands of the α-helix structure.30 As the amount of DOX 
increased, the CD intensities increased remarkably, indicat-
ing that the structure of BSA became highly ordered. The 
calculated results of the α-helical content of BSA showed 
that the α-helix structure increased from 28.2% (0% DOX) 
to 28.4% (2.5% DOX) and 30.2% (5% DOX). These findings 
suggested that the interaction between DOX and BSA-V-NPs 
enhanced as the additional amount of DOX increased.
The physical status of DOX inside the BSA-V-NPs was 
investigated using DSC. As shown in Figure 3B, the melting 
endothermic peaks of DOX were found between 200°C and 
240°C. The DSC thermogram of DOX-BSA-V-NPs (Figure 3C) 
was similar to that of BSA-V-NPs (Figure 3D), while the ther-
mogram of the physical mixture (Figure 3A) showed all the 
endothermic peaks of DOX and BSA-V-NPs, indicating the 
successful encapsulation of DOX into the BSA-V-NPs.
To provide additional evidence, Raman spectroscopy 
was also used to examine the encapsulation of DOX into the 
NPs. The Raman spectrum of DOX (Figure 4A) showed two 
strong peaks at 1,648 (e) and 1,290 cm-1 (g) corresponding 
to the amido bands, C=O and C–N stretching vibrations, 
a strong peak attributing to C–N stretching vibrations at 
1,425 cm-1 (f) and a peak at 790 cm-1 (h) corresponding 
to the bending vibrations in substituted phenyl rings. The 
Raman spectrum of the BSA-V-NPs (Figure 4B) contained 
a strong peak corresponding to the protein band between 
2,910 and 2,970 cm-1 (a), a strong broad peak at 1,657 cm-1 
attributed to the C=O stretching vibrations (b), a strong peak 
at 1,450 cm-1 due to the CH
2
 bending vibrations (c) and a 
prominent peak at 1,000 cm-1 related to the ring stretching 
in the substituted phenyl rings (d).31 The Raman spectrum 
of DOX-BSA-V-NPs (Figure 4C) was similar to that of 
BSA-V-NPs (Figure 4B), but the Raman spectrum of the 
mixture of DOX and BSA-V-NPs (Figure 4D) showed all 
??????
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Figure 1 TeM images of the nanoparticles.
Notes: (A) Bsa-V-NPs, scale bar 100 nm; (B) DOX-Bsa-V-NPs, scale bar 100 nm.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; TeM, transmission electron microscopy; V, vanillin.
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Figure 2 cD spectra of Bsa-V-NPs and DOX-Bsa-V-NPs.
Notes: (A) Bsa-V-NPs (0% DOX); (B) DOX-Bsa-V-NPs (2.5% DOX); and 
(C) DOX-Bsa-V-NPs (5% DOX).
Abbreviations: Bsa, bovine serum albumin; cD, circular dichroism; DOX, doxoru-
bicin; NPs, nanoparticles; V, vanillin.
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the peaks in Figure 4A and 4B, confirming that the DOX 
was encapsulated into the BSA-V-NPs.
stability of DOX-Bsa-V-NPs
The kinetic stability of DOX-BSA-V-NPs was determined by 
DLS. The time-dependent changes in the size of the NPs in 
0.9% NaCl and 5% glucose solutions at 37°C are shown in 
Figure 5A, while the diameter changes of 10 days storage at 
40°C and 2 months storage at 4°C are shown in Figure 5B. 
The mean particle size of DOX-BSA-V-NPs remained con-
stant for 48 hours at 37°C in 0.9% NaCl (Figure 5A,1) and 5% 
glucose (Figure 5A,2). Moreover, the size of the NPs hardly 
changed even after 10 days storage at 40°C (Figure 5B,1) and 
60 days storage at 4°C (Figure 5B,2). These results indicated 
that the DOX-BSA-V-NPs were kinetically stable and suit-
able for in vivo application.
Doxorubicin release in vitro
The release profile of DOX from the DOX-BSA-V-NPs 
in PBS buffer (pH 7.4 and pH 6.5), 10 μM GSH (pH 7.4), 
and 20 mM GSH (pH 6.5) at 37°C are shown in Figure 6 
with the free DOX as a control. The results showed that 
the diffusion of the DOX solution was fast with 100% 
accumulative release after 6, 8, and 12 hours, respectively, 
whereas the NPs exhibited a sustained release due to the 
compact BSA network and the interaction between DOX 
and NPs. To evaluate the release kinetics of DOX from the 
formulations, in vitro release data were fitted to different 
mathematical equations including zero order, first order, 
Higuchi, and Weibull using the software of DDSolver.32 Each 
release pattern fit the Weibull equation and the parameters 
are listed in Table 3. Because of the comparatively higher 
solubility of protonated DOX and weaker interactions 
between DOX and NPs at lower pH values, both the free 
DOX and DOX-BSA-V-NPs showed faster diffusion/release 
in pH 6.5 buffers than in 7.4 buffers.22,24 Moreover, the NPs 
showed quicker and greater release in greater concentration 
GSH solutions (20 mM) than in lower GSH concentration 
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Figure 3 Dsc curves.
Notes: Differential scanning calorimetric thermograms of (A) mixture of DOX and 
Bsa-V-NPs, (B) DOX, (C) DOX-Bsa-V-NPs, and (D) Bsa-V-NPs. 
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; 
V, vanillin; Dsc, differential scanning calorimetric.
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Figure 4 raman spectra of (A) DOX, (B) Bsa-V-NPs, (C) DOX-Bsa-V-NPs, and (D) mixture of DOX and Bsa-V-NPs.
Notes: a, protein band; b, c=O stretching vibrations; c, ch2 bending vibrations; d, ring stretching in the substituted phenyl rings; e and g, amido bands, c=O and c–N 
stretching vibrations; f, c–N stretching vibrations; h, bending vibrations in substituted phenyl rings.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; V, vanillin.
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solutions (10 μM) due to the presence of a large number of 
disulfide bridges in the NPs. In addition, the release curve 
of DOX-BSA-V-NPs in PBS buffer (pH 7.4) was similar to 
that in 10 μM GSH (pH 7.4), suggesting that the appearance 
of lower GSH concentrations did not significantly affect the 
release behavior. As 10 μM GSH (pH 7.4) and 20 mM GSH 
(pH 6.5) were separately used to simulate the physiological 
condition of the blood and tumor cells, the pH- and GSH-
sensitive release profiles of the NPs might be beneficial to 
increase their stability in the circulatory system and enhance 
DOX release in the tumor cells.33,34
cellular uptake and uptake mechanism
The internalization of drugs into the cancer cells is a 
prerequisite for their anticancer effects. As shown in Figure 7, 
both the intracellular uptake of free DOX and DOX-BSA-
V-NPs by BGC-823 cells showed a concentration- and 
time-dependent manner. The fluorescence of the cells 
treated with the formulations with a DOX concentration of 
6.24 μg/mL was stronger than 0.78 μg/mL (Figure 7A, C, 
and E), while that of 8 hours was stronger than 0.5 hours 
(Figure 7B, D, and F). Moreover, the CLSM images 
(Figure 7G) also demonstrated that the uptake of DOX-BSA-
V-NPs was more efficient than that of free DOX at 37°C for 
4 hours, indicating that the BSA-V-NPs enhanced the cellular 
uptake of DOX.
Understanding the intracellular fate of NPs is crucial 
for drug design due to its importance in drug delivery 
and release. As shown in Figure 8A, the internalization of 
RBITC-labeled BSA-V-NPs in BGC-823 cells was clearly 
observed (Figure 8A,2), while the nuclei and endo-lysosomes 
were separately stained in blue (Figure 8A,1) and green 
(Figure 8A,3). Colocalization between the signal of RBITC-
labeled BSA-V-NPs and the signal of fluorochrome labeled 
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Figure 5 stability of DOX-Bsa-V-NPs in different conditions.
Notes: (A,1) 0.9% Nacl solution; (A,2) 5% glucose solution; (B,1) 10 days at 40°c; (B,2) 60 days at 4°c.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; V, vanillin.
Figure 6 accumulative release of DOX from DOX-Bsa-V-NPs in PBs buffer 
(ph 7.4 and ph 6.5), 10 μM gsh (ph 7.4), and 20 mM gsh (ph 6.5) with the free 
DOX as a control. *P,0.05 and **P,0.01.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; gsh, glutathione; 
NPs, nanoparticles; PBs, phosphate-buffered saline; V, vanillin.
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cells was investigated by CLSM. As shown in Figure 8A,4, 
a lot of yellow or orange dots appeared in the overlapped 
images after incubation with RBITC-labeled BSA-V-NPs for 
4 hours, suggesting that the BSA-V-NPs were mainly located 
in the endo-lysosomes following endocytosis. As shown in 
Figure 8B, none of the inhibitors affected the uptake of free 
DOX. However, the cellular uptake of DOX-BSA-V-NPs 
was remarkably decreased by pretreatment with sucrose, 
indicating that clathrin-mediated endocytosis was the main 
uptake pathway of the NPs. These findings were consistent 
with the results of the endo-lysosome labeling experiment. 
In addition, the CLSM images also showed that DOX accu-
mulated in the nuclei (Figure 7G) although the BSA-V-NPs 
were entrapped in the endo-lysosomes after cellular uptake 
(Figure 8A), confirming the endo-lysosomal escape capabil-
ity of the BSA-V-NPs.
cytotoxicity assay
Cytotoxicity studies suggested that free DOX and DOX-BSA-
V-NPs inhibited proliferation of BGC-823 cells in a dose-
dependent manner (Figure 9). Compared with free DOX, the 
cell inhibition rate of DOX-BSA-V-NPs was slightly higher 
and the IC
50
 values calculated for DOX and DOX-BSA-V-
NPs were 4.007±0.378 and 3.693±0.525 μg/mL, respectively, 
after treatment for 48 hours, indicating that the NPs produced 
a stronger antitumor activity. This can be attributed to the 
sustained drug release pattern from DOX-BSA-V-NPs, as 
well as the higher cellular uptake of the NPs.
Biodistribution examination in vivo
To examine the in vivo distribution of the BSA-V-NPs, the 
lipophilic fluorescent dye DiR-labeled BSA-V-NPs were 
administrated to the xenograft Heps tumor-bearing mice via 
tail vein injection. The DiR signal was clearly observed at 
the tumor site at 4 hours postinjection, enhanced at 6 hours 
and remained up to 24 hours (Figure 10), indicating that the 
BSA-V-NPs have tumor targeting ability and can be retained 
in the tumors.
In order to quantitatively assess the in vivo distribution 
of the DOX formulations, the Heps tumor-bearing mice 
were sacrificed at various time points after administration 
of free DOX, DOX-BSA-NPs, and DOX-BSA-V-NPs. The 
concentration of DOX in the heart and tumor was determined 
by HPLC equipped with a fluorescence detector. The DOX 
concentrations for DOX-BSA-V-NPs and DOX-BSA-NPs 
in the tumors were 1.53-, 0.70-, 0.98-, and 1.52-fold as well 
as 1.36-, 0.40-, 0.58-, and 0.96-fold higher than that of free 
DOX after 6, 12, 24, and 48 hours, respectively. However, 
there was no significant difference between the two NP 
groups. On the contrary, the DOX concentration for free 
DOX in the heart was significantly higher than that of the 
DOX NPs. Hence, compared with free DOX, the NP formula-
tions showed enhanced tumor accumulation and decreased 
heart distribution (Figure 11), indicating that BSA-NPs could 
improve the biodistribution of DOX and the cardiac toxicity 
could be greatly reduced as a result. The constant concentra-
tion of DOX in the tumor from 12 to 48 hours postinjection 
indicated that the NPs could be retained in the tumor for a 
long time period. This finding was consistent with the NIRF 
observation.
In vivo antitumor efficacy
To investigate the antitumor effect of DOX NPs, the survival 
study in Heps tumor-bearing mice was undertaken. The detailed 
data of mean survival time are shown in Figure 12 and the cal-
culated parameters are presented in Table 4. The mean survival 
time and lifespan of tumor-bearing mice were significantly pro-
longed by the NPs, whereas the free DOX had no obvious effect 
(Table 4). The result indicated that the NPs were more effective 
than free DOX to increase the lifespan of the tumor-bearing 
Table 3 Weibull parameters for DOX release data modeling
Formulation Release medium Fitting equation r
Free DOX PBs (ph 7.4) F=1-e-0.715(t+0.037)0.693 0.9955
PBs (ph 6.5) F=1-e-0.291(t+1.190)1.317 0.9983
10 μM gsh (ph 7.4) F=1-e-0.278(t+0.874)1.225 0.9994
20 mM gsh (ph 6.5) F=1-e-0.569(t+0.606)1.125 0.9998
DOX-Bsa-V-NPs PBs (ph 7.4) F=1-e-0.237(t-0.929)0.255 0.9799
PBs (ph 6.5) F=1-e-0.450(t-0.986)0.158 0.9749
10 μM gsh (ph 7.4) F=1-e-0.331(t-0.995)0.150 0.9782
20 mM gsh (ph 6.5) F=1-e-0.598(t-0.878)0.285 0.9919
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; F, drug released fraction at time t; gsh, glutathione; NPs, nanoparticles; PBs, phosphate-buffered saline; 
r, correlation coefficient; t, release time; V, vanillin.
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Figure 7 cellular uptake of free DOX and DOX-Bsa-V-NPs.
Notes: cellular internalization of free DOX and DOX-Bsa-V-NPs observed by (A, B) inverted fluorescence microscopy (100× magnification), (C–F) flow cytometry, and 
(G) clsM (400× magnification). (C) 1, control; 2, free DOX (0.78 μg/ml, 2 hours); 3, DOX-Bsa-V-NPs (0.78 μg/ml, 2 hours); 4, free DOX (6.24 μg/ml, 2 hours); 5, DOX-
Bsa-V-NPs (6.24 μg/ml, 2 hours). (D) 1′, control; 2′ free DOX (1.56 μg/ml, 0.5 hours); 3′, DOX-Bsa-V-NPs (1.56 μg/ml, 0.5 hours); 4′, free DOX (1.56 μg/ml, 8 hours); 
5′, DOX-Bsa-V-NPs (1.56 μg/ml, 8 hours). (E) concentration-dependent uptake of free DOX and DOX-Bsa-V-NPs. The cells were exposed to various concentrations of 
the DOX formulations at 37°C for 4 hours, and subsequently determined by flow cytometry. (F) Time-dependent uptake of free DOX and DOX-Bsa-V-NPs. The cells were 
treated with the DOX formulations at a concentration of 1.56 μg/ml at 37°C and then analyzed by flow cytometry. (G) DOX (1.56 μg/ml, 4 hours) and DOX-Bsa-V-NPs 
(1.56 μg/ml, 4 hours).
Abbreviations: Bsa, bovine serum albumin; clsM, confocal laser scanning microscopy; DaPI, 4′,6-diamidino-2-phenylindole; DOX, doxorubicin; NPs, nanoparticles; V, vanillin.
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Figure 8 cellular uptake mechanism investigated by (A) clsM and (B) inverted fluorescence microscopy.
Notes: Uptake pathways of DOX-Bsa-V-NPs in Bgc-823 cells studied by using (A) lysoTracker green (400× magnification) and (B) endocytic inhibitors (100× magnifica-
tion). (A,1) DaPI; (A,2) rBITc-labeled Bsa-V-NPs; (A,3) lysoTracker green; (A,4) merge.
Abbreviations: Bsa, bovine serum albumin; clsM, confocal laser scanning microscopy; DaPI, 4′,6-diamidino-2-phenylindole; DOX, doxorubicin; rBITc, rhodamin B 
isothiocyanate; NPs, nanoparticles; V, vanillin.
mice. In addition, the group treated with DOX-BSA-V-NPs had 
the longest mean survival time and the biggest survivability 
rate, and there were significant differences between the DOX-
BSA-V-NPs group and other groups (the P-values calculated 
by one-tailed t-tests are shown in Table S1).
To further evaluate the antitumor effect of the DOX 
NPs, a tumor suppression experiment was performed using 
the Heps tumor-bearing mice. The tumor volume and tumor 
inhibition rate of different treatments were exhibited in 
Table 5. The tumor volume of the DOX formulations was 
smaller than that of normal saline, indicating that DOX could 
inhibit tumor growth. Compared with free DOX, the tumor 
volume of the NPs was even smaller, suggesting that the 
tumor suppression of DOX-loaded NPs was more potent. 
Moreover, no significant difference between the two NP 
groups was found in this study.
The hearts and tumors were washed, fixed in 10% for-
malin, embedded in paraffin blocks, sliced into 5 mm thick 
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3886
li et al
???
???
??
??
??
??
??
??
?? ?????? ????? ????? ????? ?????????????????????? ??
???
?????
?????
????
?
???? ????
??
??
?? ??
?
?????????????????????
Figure 9 In vitro cytotoxicity of DOX and DOX-Bsa-V-NPs against Bgc-823 cells 
for 48 hours of treatment assessed by using the ccK-8 assay. *P,0.05, **P,0.01.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; 
V, vanillin.
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Figure 10 NIrF images of the xenograft heps tumor-bearing mouse after intravenous injection of Dir-Bsa-V-NPs.
Abbreviations: BSA, bovine serum albumin; DiR, 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindotricarbocyanine iodide; DOX, doxorubicin; NIRF, near-infrared fluorescence; 
NPs, nanoparticles; V, vanillin.
sections, and placed onto glass slides.35,36 After staining with 
HE for microscopic observation, the images of pathology 
analysis are displayed in Figure 13. In a normal saline group, 
myocardial fibers arranged neatly (Figure 13A,1), while a 
slight extension of the myocardial fiber gap was observed 
in the NP groups (Figure 13A,3 and 13A,4, black arrow) 
and moderate focal edema necrosis (Figure 13A,2, black 
arrow) and focal band fibrosis (Figure 13A,2, red arrow) 
were noticed in the free DOX group. Moreover, the tumors 
exhibited typical pathological features in the control group, 
including closely packed,36 rich cytoplasm, large irregular 
karyons, and more nuclear division,37 while inflammatory 
infiltration (Figure 13B,2, red arrow) and cell apoptosis 
and spotty necrosis (Figure 13B,2, 13B,3, and 13B,4, black 
arrow) were observed in the tumor section of the DOX 
groups. The results presented evidence of the effective anti-
tumor effect of the DOX formulations in vivo. In particular, 
compared with free DOX and DOX-BSA-NPs groups, the 
tumor tissues treated with DOX-BSA-V-NPs had the largest 
necrotic area. Hence, the results from histopathology analysis 
was in good accordance with other in vitro and in vivo find-
ings and proved again the reduced side effects and enhanced 
antitumor activity of the NPs compared with free DOX. 
As the DOX distribution of the two NPs in tumor showed no 
significant difference, the greater in vivo antitumor effect of 
DOX-BSA-V-NPs than DOX-BSA-NPs in this study could 
be attributed to the existence of a Schiff base.
Conclusion
In this study, DOX was successfully loaded in Schiff 
base-based BSA-NPs with a diameter smaller than 200 nm 
and a high DLE of up to 27.77%±0.50%. In vitro studies 
indicated that the DOX-BSA-V-NPs could be quickly and 
effectively internalized in BGC-823 cells, mainly through 
clathrin-mediated endocytosis, and DOX accumulated in 
the nuclei after release from endo-lysosomes. The CCK-8 
test demonstrated that the DOX-BSA-V-NPs had a relatively 
greater cytotoxicity than free DOX against BGC-823 cells. 
An in vivo distribution study indicated that the BSA-V-NPs 
possessed outstanding tumor targeting capacity and DOX 
could be delivered to the tumor. The DOX-BSA-V-NPs 
also showed superior extension of survival time than free 
DOX and DOX-BSA-NPs, and greater tumor suppression 
than free DOX. Besides, the cardiac toxicity of DOX was 
largely reduced by the NPs. All of these results indicated 
that tumor-targeted Schiff base-based BSA-NPs can be an 
effective drug carrier to enhance the anticancer effect of 
chemotherapy agents.
International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3887
DOX-loaded albumin nanoparticles
???????? ??????????? ?????????????
? ????
????
????
?
?
?
?
?
?
?
? ??? ? ? ??? ?????????
???
????
?????
????
?
? ?? ?? ??
??
??
??
??
??
??
??
??
??
???
????
????
????
?
?
?? ???????????? ? ? ? ? ?? ?? ??
?
???
???
???
???
?
Figure 11 Biodistribution of free DOX, DOX-Bsa-NPs and DOX-Bsa-V-NPs in (A) heart and (B) tumor.
Notes: Time profiles of DOX accumulated in the (A) heart and (B) tumor after intravenous injection of different DOX formulations with a DOX dose of 5 mg kg-1. DOX/
heart and DOX/tumor are the ratios of the DOX amount in the heart (μg) and tumor (μg) to the tumor weight (g), respectively. *P,0.05, **P,0.01.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; V, vanillin.
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Figure 12 survival curves of heps tumor-bearing mice after administration with normal saline and different DOX formulations with a DOX dose of 5 mg⋅kg-1⋅day-1 for 3 days.
Notes: *P,0.05 vs normal saline group; ΔP,0.05 vs free DOX group; **P,0.01 vs normal saline group; #P,0.05 vs DOX-Bsa-NPs group; ##P,0.01 vs free DOX group.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; V, vanillin.
Table 5 Tumor inhibition effects of normal saline and different 
DOX formulations on heps tumor-bearing mice with a doxoru-
bicin dose of 5 mg⋅kg-1⋅day-1 for 3 days
Group Tumor volume (cm3) Tumor inhibition 
rate (%)
Normal saline 1.75±1.01
Free DOX 1.42±1.19 19.2
DOX-Bsa-NPs 0.772±0.370a 55.94
DOX-Bsa-V-NPs 0.760±0.466a 56.66
Note: aP,0.05 compared with normal saline.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; 
V, vanillin.
Table 4 survivability of heps tumor-bearing mice after 
administration with normal saline and different DOX formulations 
with a DOX dose of 5 mg⋅kg-1⋅day-1 for 3 days
Group Mean survival time 
(days)
Increase of lifespan (%)
Normal saline 14.0±2.00
Free DOX 15.33±1.75 9.52
DOX-Bsa-NPs 19.0±4.34a,b 39.29
DOX-Bsa-V-NPs 24.83±6.43c,d,e 57.14
Notes: aP,0.05 compared with normal saline; bP,0.05 compared with free DOX; 
cP,0.01 compared with normal saline; dP,0.01 compared with free DOX; and 
eP,0.05 compared with DOX-Bsa-NPs.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; 
V, vanillin.
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Figure 13 he staining of (A) heart and (B) tumor (200× magnification).
Notes: heps tumor-bearing mice were randomly divided into four treatment groups and were administered with (1) normal saline, (2) free DOX, (3) DOX-Bsa-NPs, 
and (4) DOX-Bsa-V-NPs. Black arrow in (A,1), myocardial fibers arranged neatly; black arrow in (A,2), moderate focal edema necrosis; black arrow in (A,3) and (A,4), a 
slight extension of the myocardial fiber gap; red arrow in (A,2), focal band fibrosis; red arrow in (B,2), inflammatory infiltration; black arrow in (B,2), (B,3) and (B,4), cell 
apoptosis and spotty necrosis.
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; he, hematoxylin and eosin; NPs, nanoparticles; V, vanillin.
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Table S1 P-values calculated by one-tailed t-test
Group Free DOX DOX-BSA-NPs DOX-BSA-V-NPs
Normal saline 0.124 0.0141 0.00139
Free DOX 0.0419 0.00291
DOX-Bsa-NPs 0.0476
Abbreviations: Bsa, bovine serum albumin; DOX, doxorubicin; NPs, nanoparticles; V, vanillin.
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